secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2023-05-23T23:59:59+00:00
Accession:  0001104659-23-063688
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.05, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC discontinues early gene therapy programs, CFO terminated, vatiquinone Phase 3 misses primary endpoint
--------------------------------------------------------------------------------

- Discontinues preclinical/early gene therapy programs; workforce reduction of ~8%; expects 15% OPEX savings in 2023; severance costs ~$7M.
- CFO Emily Hill terminated effective immediately; employment ends Aug 20, 2023; eligible for severance without cause.
- Phase 3 MOVE-FA trial of vatiquinone in Friedreich ataxia misses primary endpoint (mFARS change, p=0.14). Subscales and completers analysis show signals.
- Company to discuss potential registration path with regulators despite missing primary endpoint; vatiquinone well tolerated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000110465923063688/0001104659-23-063688-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000110465923063688/tm2316598d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-063688

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer